Work

Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.5_suppl.354

Authors: Brian I. Rini, Bernard J. Escudier, M Dror Michaelson, Sylvie Negrier, Martin Eric Gore, Stephane Oudard, Joseph Clark, Jamal Christo Tarazi, Brad Rosbrook, Sinil Kim, Robert John Motzer

Institutions: Loyola University Medical Center, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Massachusetts General Hospital, Hôpital Européen Georges-Pompidou, Centre Léon Bérard, Royal Marsden Hospital, Loyola Medicine

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2559918850

Cites:

Cited by: 26

Related to: 10